ETF PROAI

IGIBvsXPH

iShares 5-10 Year Investment Grade Corporate Bond ETF against SPDR S&P Pharmaceuticals ETF — the fee, the flows, the book, and a year head-to-head.

One year, growth of $100
IGIB 93XPH 132Oct 25Oct 26GROWTH OF $100
Head to head
IGIBXPH
Expense ratio0.040%0.35%
Assets$18.6B$524M
Net flow, 1 month+$565M−$43M
Net flow, 1 year+$3.6B+$271M
Return, YTD-6.9%+13.6%
Return, 1 year-7.3%+31.8%
Avg daily volume3.8M188K
Holdings274441
ListedJan 5, 2007Jun 19, 2006
Options marketYesYes

MARKED CELLS LEAD ON THAT LINE · LOWER FEE, LARGER ASSETS, STRONGER FLOWS & RETURNS

THE DESK BRIEF

Flows, fee cuts, and closure risk on the funds you watch — every trading morning.